Form 4: Chimerix Chief Medical Officer Disposes of Shares Following Merger with Jazz Pharmaceuticals
SEC Form 4
Allen S. Melemed, Chief Medical Officer of Chimerix, reports the disposition of shares and stock options following the company's merger with Jazz Pharmaceuticals.
Summary
- Allen S. Melemed, the Chief Medical Officer of Chimerix, filed a Form 4 detailing changes in beneficial ownership of Chimerix securities.
- The filing is related to the merger between Chimerix and Jazz Pharmaceuticals, where Jazz acquired Chimerix for $8.55 per share.
- Melemed disposed of 173,852 shares of common stock at a price of $8.55 per share due to the merger agreement.
- Outstanding stock options were treated differently based on whether they were 'in the money' (exercise price less than $8.55).
- In-the-money options, to the extent unvested, were accelerated and became fully vested and exercisable.
- Vested in-the-money options were cancelled and converted into the right to receive a cash payment equal to the difference between $8.55 and the exercise price, multiplied by the number of shares subject to the option.
- Options that were not in the money were cancelled with no consideration.
- Restricted stock units (RSUs) were cancelled and converted into the right to receive a cash payment equal to $8.55 multiplied by the number of shares subject to the RSU.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The merger provides a defined cash value for shareholders and option holders, but also marks the end of Chimerix as an independent entity. The deal appears to have closed as expected.
Positives
- The merger provided a cash payment of $8.55 per share for Chimerix shareholders.
- In-the-money stock options were accelerated and cashed out, providing value to option holders.
Negatives
- Out-of-the-money stock options were cancelled with no consideration.
- The merger resulted in the cancellation of existing equity and derivative holdings.
Future Outlook
The document does not contain specific forward-looking statements beyond the completion of the merger.
Industry Context
The acquisition of Chimerix by Jazz Pharmaceuticals reflects ongoing consolidation trends in the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.
Comparison to Industry Standards
- Merger and acquisition (M&A) transactions in the pharmaceutical industry often involve a premium paid to the target company's shareholders.
- The $8.55 per share offer price represents a premium over Chimerix's pre-announcement trading price, which is a typical feature of M&A deals.
- Comparable transactions include Gilead Sciences' acquisition of Kite Pharma and Takeda Pharmaceutical's acquisition of Shire, both of which involved significant premiums and strategic rationale.
Stakeholder Impact
- Shareholders received $8.55 per share in cash.
- Employees may experience changes as a result of the acquisition by Jazz Pharmaceuticals.
- Customers and partners may see changes in the availability or development of Chimerix's products.
Key Dates
| Date | Description |
|---|---|
| March 4, 2025 | Date of the Agreement and Plan of Merger between Chimerix, Jazz Pharmaceuticals, and Pinetree Acquisition Sub, Inc. |
| March 10, 2025 | Date Allen S. Melemed acquired 20,977 shares under the Issuer's Employee Stock Purchase Plan. |
| April 17, 2025 | Expiration date of the tender offer by Parent and Purchaser for all outstanding shares of common stock of Chimerix. |
| April 21, 2025 | Date of the merger between Purchaser and Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent. |
| June 18, 2030 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $3.11. |
| January 21, 2031 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $9.28. |
| January 17, 2032 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $5.62. |
| January 16, 2033 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $1.97. |
| January 31, 2034 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $0.93. |
| January 06, 2035 | Expiration date of Employee Stock Option (Right to Buy) with exercise price of $3.66. |
Keywords
Merger, Chimerix, Jazz Pharmaceuticals, Form 4, Beneficial Ownership, Stock Options, RSU, Allen S. Melemed
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.